Objective To compare the effects of using different treatment regimens after remission for acute promyelocytic leukemia (APL) on long-term survival. Methods Retrospective analysis of long-term survival in 111 APL patients using different treatment regimens after remission. Group 1: all-trans vincristine (ATRA), arsenic trioxide (As2O3), and chemotherapy sequential treatment group, 40 cases; Group 2: alternating ATRA and chemotherapy treatment group, 30 cases; Group 3: alternating As2O3 and chemotherapy treatment group, 26 cases; Group 4: chemotherapy alone group, 15 cases. The median follow-up was 32 (6 to 185) months. Results At the follow-up cut-off, 85 patients survived disease-free, 18 died, and 8 were lost to follow-up. 36, 23, 21, and 5 patients survived in the 4 groups; 3, 5, 5, and 5 died; 16, 12, 11, and 1 survived ≥3 years in the 4 groups, respectively. 111 patients had an expected 5-year overall survival (OS) of (78.3±4.9)% and a 5-year relapse-free survival (RFS) of ( 76.9±5.1)%. There were 21 relapses on treatment. Conclusions Patients with APL in remission who received combination therapy had better OS and RFS than chemotherapy alone. sequential treatment regimens of ATRA, As2O3, and chemotherapy were most beneficial for long-term survival.